All In Biotech

NDA 021676 · Bayer Hlthcare

Yaz

Drospirenone, Ethinyl Estradiol · Oral

Last checked: Nov 19, 2026Latest source record: May 19, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Mar 16, 2006

Approved uses

2

Original approval plus efficacy supplements

Registered trials

146

48 Phase 3, 7 recruiting

FAERS reports

31,300

24,198 serious, 376 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke [see Contraindications ( 4 )] . WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS See full prescribing information for complete boxed warning. • Women over 35 years old who smoke should not use Yaz ( 4 ). • Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. ( 4 )

What it is approved for

From the label in effect May 29, 2025.

Yaz is a combination of drospirenone, a progestin, and ethinyl estradiol, an estrogen, indicated for use by females of reproductive potential to: • Prevent pregnancy. ( 1.1 ) • Treat symptoms of premenstrual dysphoric disorder (PMDD) for females of reproductive potential who choose to use an oral contraceptive for contraception. ( 1.2 ) • Treat moderate acne for women at least 14 years old only if the patient desires an oral contraceptive for birth control. ( 1.3 ) 1.1 Oral Contraceptive Yaz ® is indicated for use by females of reproductive potential to prevent pregnancy. 1.2 Premenstrual Dysphoric Disorder (PMDD) Yaz is also indicated for the treatment of symptoms of premenstrual dysphoric disorder (PMDD) in females of reproductive potential who choose to use an oral contraceptive as their method of contraception. The effectiveness of Yaz for PMDD when used for more than three menstrual cycles has not been evaluated. The essential features of PMDD according to the Diagnostic and Statistical Manual-4th edition (DSM-IV) include markedly depressed mood, anxiety or tension, affective lability, and persistent anger or irritability. Other features include decreased interest in usual activities, difficulty concentrating, lack of energy, change in appetite or sleep, and feeling out of control. Physical symptoms associated with PMDD include breast tenderness, headache, joint and muscle pain, bloating and weight gain. In this disorder, these symptoms occur regularly during the luteal phase and remit within a few days following onset of menses; the disturbance markedly interferes with work or school, or with usual social activities and relationships with others. Diagnosis is made by healthcare providers according to DSM-IV criteria, with symptomatology assessed prospectively...

Mechanism: COCs lower the risk of becoming pregnant primarily by suppressing ovulation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • YAZ · DROSPIRENONE 3MG; ETHINYL ESTRADIOL 0.02MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Drospirenone" as an intervention, any sponsor and status, largest first.

All 146 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pain10,333
  • injury8,764
  • pulmonary embolism6,448
  • deep vein thrombosis5,876
  • anxiety5,267
  • emotional distress5,096
  • cholecystitis chronic4,476
  • gallbladder disorder3,273
  • cholelithiasis3,258
  • general physical health deterioration2,535
  • abdominal pain2,119
  • nausea2,023

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
200619
2007213
20082,509
20092,361
20101,750
20118,672
20127,360
20133,487
20141,798
2015588
2016450
2017278
2018271
2019247
2020239
2021189
2022202
2023203
2024145
2025175
2026143

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Yaz (Ethinyl Estradiol/Drospirenone)

2024 spending

$101K

Beneficiaries

70

288 claims

Per beneficiary

$1,447

$5.89 per unit

View as table
YearSpending
2020$101,575
2021$116,832
2022$112,206
2023$114,419
2024$101,280

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 312 on PubMed

Sponsor: Bayer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.